Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;37(2):147-157.
doi: 10.1055/s-0037-1602423. Epub 2017 May 16.

Motor Complications of Dopaminergic Medications in Parkinson's Disease

Maria Eliza Freitas  1 , Christopher W Hess  2 , Susan H Fox  1
Affiliations
Review

Motor Complications of Dopaminergic Medications in Parkinson's Disease

Maria Eliza Freitas et al. Semin Neurol. 2017 Apr.

Abstract

Motor complications are a consequence of the chronic treatment of Parkinson's disease (PD) and include motor fluctuations (wearing-off phenomenon) and levodopa-induced dyskinesia. Both can have a significant impact on functionality and quality of life; thus, proper recognition and management is essential. The phenomenology and temporal relationship of motor complications to the schedule of levodopa dosing can be helpful in characterizing them. There are several therapeutic approaches to motor complications, including pharmacological and surgical options. The authors summarize the different types of motor complications according to phenomenology and the currently available medical treatments, including ongoing trials for the management of this condition.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Motor fluctuations according to “ON”, “Transition ON-OFF-ON”, and "OFF" state.
See this image and copyright information in PMC

References

    1. Hornykiewicz O. A brief history of levodopa. J Neurol. 2010;257(Suppl 2):S249–S252. doi: 10.1007/s00415-010-5741-y. - DOI - PubMed
    1. Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015;30(1):80–89. doi: 10.1002/mds.26125. - DOI - PubMed
    1. Anderson E, Nutt J. The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications. Parkinsonism Relat Disord. 2011;17(8):587–592. doi: 10.1016/j.parkreldis.2011.03.014. - DOI - PubMed
    1. Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol. 2010;257(Suppl 2):S253–S261. doi: 10.1007/s00415-010-5728-8. - DOI - PubMed
    1. Widnell K. Pathophysiology of motor fluctuations in Parkinson's disease. Mov Disord. 2005;20(Suppl 11):S17–S22. doi: 10.1002/mds.20459. - DOI - PubMed

Publication types

MeSH terms

Substances